[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Araujo
R
R
Fundació Institut Català de Farmacologia. Hospitals Vall d'Hebron. Barcelona.
Agustí
A
A
D000077284:Abciximab; D000208:Acute Disease; D000789:Angina, Unstable / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D017073:Atherectomy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000188:drug therapy* / Q000628:therapy; D000077542:Eptifibatide; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D010455:Peptides / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D013577:Syndrome; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D006493:Heparin; D000077466:Tirofiban; D000077542:Eptifibatide; D001241:Aspirin; D000077284:Abciximab